Abstract
Objective: Soluble receptor for advanced glycation end products (sRAGE) levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, hypertension and renal failure. This study evaluated the relationship between sRAGE concentrations and urinary albumin excretion in patients with essential hypertension. Methods: A total of 200 consecutive patients with essential hypertension were enrolled and were divided into 3 groups. Results: Plasma sRAGE levels were significantly lower in hypertensive patients with micro- or macroalbuminuria compared with those in hypertensive patients with normoalbuminuria, and the values in the macroalbuminuria group were even lower than in the microalbuminuria group (128.6±24.2, 244.6±37.6313.6±30.7 pg/ml respectively). In addition, plasma sRAGE level was an independent determinant of log urinary albumin excretion in patients with essential hypertension (β=0.267, P<0.05). Conclusions: sRAGE may play a role in the pathogenic processes that link albuminuria, chronic inflammation and oxidative stress in hypertensive patients.
Keywords: Albuminuria, hypertension, receptor for advanced glycation end products.
Current Vascular Pharmacology
Title:Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria
Volume: 13 Issue: 2
Author(s): Huan Zheng, Lingyan Yuan, Nanzi Xie, Huifeng Xu, Xiaoyun Xie and Ming Luo
Affiliation:
Keywords: Albuminuria, hypertension, receptor for advanced glycation end products.
Abstract: Objective: Soluble receptor for advanced glycation end products (sRAGE) levels have been found to be decreased in chronic inflammatory diseases including atherosclerosis, hypertension and renal failure. This study evaluated the relationship between sRAGE concentrations and urinary albumin excretion in patients with essential hypertension. Methods: A total of 200 consecutive patients with essential hypertension were enrolled and were divided into 3 groups. Results: Plasma sRAGE levels were significantly lower in hypertensive patients with micro- or macroalbuminuria compared with those in hypertensive patients with normoalbuminuria, and the values in the macroalbuminuria group were even lower than in the microalbuminuria group (128.6±24.2, 244.6±37.6313.6±30.7 pg/ml respectively). In addition, plasma sRAGE level was an independent determinant of log urinary albumin excretion in patients with essential hypertension (β=0.267, P<0.05). Conclusions: sRAGE may play a role in the pathogenic processes that link albuminuria, chronic inflammation and oxidative stress in hypertensive patients.
Export Options
About this article
Cite this article as:
Zheng Huan, Yuan Lingyan, Xie Nanzi, Xu Huifeng, Xie Xiaoyun and Luo Ming, Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria, Current Vascular Pharmacology 2015; 13 (2) . https://dx.doi.org/10.2174/1570161111666131209143650
DOI https://dx.doi.org/10.2174/1570161111666131209143650 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NGAL is a Precocious Marker of Therapeutic Response
Current Pharmaceutical Design A New Gene Delivery System Based on Controlled Release Technology
Current Drug Delivery Autonomic Dysfunction and Depression: A Biomarker of MDD Across the Life Span
Current Psychiatry Reviews The Promise of Plant-Derived Substances as Inhibitors of Arginase
Mini-Reviews in Medicinal Chemistry Protease-Activated Receptor-2 Antagonists and Agonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Agonistic and Antagonistic Bivalent Ligands for Serotonin and Dopamine Receptors Including their Transporters
Current Topics in Medicinal Chemistry Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Diabetic Cardiomyopathy: Clinical and Metabolic Approach
Current Vascular Pharmacology Arginine Deprivation as a Targeted Therapy for Cancer
Current Pharmaceutical Design Trace and Minor Element Concentrations in Aqueous Extract of the Herbal Medicinal Plants Tamarindus indica and Hibiscus sabdiffora
Current Nutrition & Food Science Anti-Angiogenesis in the Treatment of Genito-Urinary Cancers: Last Updates
Current Angiogenesis (Discontinued) Effects of Endothelins on Cardiac and Vascular Cells: New Therapeutic Target for the Future?
Current Vascular Pharmacology Henoch-Schönlein Purpura in Children: An Updated Review
Current Pediatric Reviews Novel Therapeutic Targets for Management of Type-2 Diabetes Mellitus
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pleiotropic Effects of Drugs Inhibiting the Renin-Angiotensin-Aldosterone System
Current Pharmaceutical Design Endothelial Dysfunction and Angiogenesis in Autosomal Dominant Polycystic Kidney Disease
Current Hypertension Reviews Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design Advanced Glycation Endproducts and Diabetes. Beyond Vascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets High-dose Vitamin D Supplementation on Type 1 Diabetes Mellitus Patients: Is there an Improvement in Glycemic Control?
Current Diabetes Reviews Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice
Current Medicinal Chemistry